Cancer Type: Lymphoma

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201411010

A phase 1/2 study of ALT-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab

201611137

Phase I Trial of Duvelisib (IPI-145) in Combination with Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

201612158

Lymphoma SPORE: LS1293: Effect of Vitamin D Replacement on Tumor Response and Survival Parameters for Vitamin D Insufficient Patients with Cancer

201704108

A Pilot Trial of Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients with DLBCL

201709185

ILyAD (Indolent Lymphoma And Vitamin D): A phase III double blind, prospective randomized trial to evaluate the supplemental effect of vitamin D (cholecalciferol) on progression-free survival in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy

201710050

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

201804151

Pilot Study of a Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients with Follicular Lymphoma

201807106

A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

201811110

A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

202005165

Phase II Trial with Safety Lead-in of Duvelisib Maintenance after Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas